Q-omics provides the consensus-scored WRAP53 profile across patient tissues and cancer cell-line models. WRAP53 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WRAP53 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, WRAP53 RNA expression shows 18,785 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where WRAP53 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WRAP53 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WRAP53 survival associations across molecular data types. WRAP53 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WRAP53 RNA expression–survival associations across cancer types. High WRAP53 expression shows unfavorable associations in ACC, MESO, LIHC, KIRC and LGG, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WRAP53 RNA expression.
This table summarizes WRAP53 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WRAP53. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WRAP53 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, STAD, BLCA and LIHC. The KIRC box plot shows higher WRAP53 RNA expression in tumor versus normal tissue (log2 FC = +0.377, t-test p < 0.001).
This table shows molecular features associated with WRAP53 in patient tissues and cancer cell lines. In patient samples, WRAP53 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WRAP53 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
